Ausgabe 1/2015
Inhalt (23 Artikel)
Cost-effectiveness and affordability of community mobilisation through women’s groups and quality improvement in health facilities (MaiKhanda trial) in Malawi
Tim Colbourn, Anni-Maria Pulkki-Brännström, Bejoy Nambiar, Sungwook Kim, Austin Bondo, Lumbani Banda, Charles Makwenda, Neha Batura, Hassan Haghparast-Bidgoli, Rachael Hunter, Anthony Costello, Gianluca Baio, Jolene Skordis-Worrall
An approach to prioritization of medical devices in low-income countries: an example based on the Republic of South Sudan
Richard J Lilford, Samantha L Burn, Karin D Diaconu, Peter Lilford, Peter J Chilton, Victoria Bion, Carole Cummins, Semira Manaseki-Holland
Cost-effectiveness of using a social franchise network to increase uptake of oral rehydration salts and zinc for childhood diarrhea in rural Myanmar
David Bishai, Karampreet Sachathep, Amnesty LeFevre, Hnin New Nwe Thant, Min Zaw, Tin Aung, Willi McFarland, Dominic Montagu
Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females
Jens Olsen, Tine Rikke Jørgensen
The determinants of technical efficiency of a large scale HIV prevention project: application of the DEA double bootstrap using panel data from the Indian Avahan
Aurélia Lépine, Anna Vassall, Sudhashree Chandrashekar
Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia
Jaime E Ordóñez, John Jairo Orozco
Cost-effectiveness of live oral attenuated human rotavirus vaccine in Tanzania
George M Ruhago, Frida N Ngalesoni, Bjarne Robberstad, Ole F Norheim
Health care: the challenge to deal with uncertainty and value judgment
Marcos Bosi Ferraz
The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims
Cindy Garris, Manan Shah, Eileen Farrelly
Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components
Panagiotis Stafylas, Georgia Kourlaba, Magda Hatzikou, Dimitrios Georgiopoulos, Pantelis Sarafidis, Nikolaos Maniadakis
Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain
Álvaro Hidalgo-Vega, Renata Villoro, Juan Antonio Blasco, Pablo Talavera, Belén Ferro, Oana Purcaru
Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model
Philip McEwan, Thomas Ward, Hayley Bennett, Klas Bergenheim
Cost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in Sweden
Oskar Eklund, Faraz Afzal, Fredrik Borgström
Cost-effectiveness analysis of routine immunization and supplementary immunization activity for measles in a health district of Benin
Landry Kaucley, Pierre Levy
Is chest X-ray screening for lung cancer in smokers cost-effective? Evidence from a population-based study in Italy
Paolo Pertile, Albino Poli, Lorenzo Dominioni, Nicola Rotolo, Elisa Nardecchia, Massimo Castiglioni, Massimo Paolucci, William Mantovani, Andrea Imperatori
Matching comprehensive health insurance reimbursements to their real costs: the case of antenatal care visits in a region of Peru
Daniel Cobos Muñoz, Kristian Schultz Hansen, Fern Terris-Prestholt, Fiona Cianci, José Enrique Pérez-Lu, Aldo Lama, Patricia J. García
New all oral therapy for chronic hepatitis C virus (HCV): a novel long-term cost comparison
Jennifer M. Poonsapaya, Michael Einodshofer, Heather S. Kirkham, Pheophilus Glover, Janeen DuChane
Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling study
An Tran-Duy, Annelies Boonen, Mart A. F. J. van de Laar, Johan L. Severens
Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods
Julian Nam, Andrew Briggs, Jamie Layland, Keith G. Oldroyd, Nick Curzen, Arvind Sood, Kanarath Balachandran, Raj Das, Shahid Junejo, Hany Eteiba, Mark C. Petrie, Mitchell Lindsay, Stuart Watkins, Simon Corbett, Brian O’Rourke, Anna O’Donnell, Andrew Stewart, Andrew Hannah, Alex McConnachie, Robert Henderson, Colin Berry
The revenue generated from clinical chemistry and hematology laboratory services as determined using activity-based costing (ABC) model
Kasaw Adane, Zenegnaw Abiy, Kassu Desta
Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey
Guvenc Kockaya, Akin Kose, Fatma Betul Yenilmez, Oktay Ozdemir, Ece Kucuksayrac
Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK
Yogesh Suresh Punekar, Graeme Roberts, Afisi Ismaila, Martin O’Leary
Efficiency of private and public primary health facilities accredited by the National Health Insurance Authority in Ghana
Robert Kaba Alhassan, Edward Nketiah-Amponsah, James Akazili, Nicole Spieker, Daniel Kojo Arhinful, Tobias F Rinke de Wit